Abstract
The article presents the experience and clinical and immunological effectiveness of the use of recombinant human interleukin-2. The accumulated clinical experience of the use of recombinant interleukin-2 in patients of different age groups indicates the validity and expediency of including the drug in the basic therapy of severe bacterial and viral infections, oncological diseases, simultaneously with antimicrobial chemotherapy in order to normalize immunological parameters and improve the clinical course of the disease, as well as for timely and complete resolution of the inflammatory process.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
